Publication: A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients
Issued Date
2005-10-06
Resource Type
ISSN
13596535
Other identifier(s)
2-s2.0-25444499748
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antiviral Therapy. Vol.10, No.6 (2005), 761-767
Suggested Citation
Jintanat Ananworanich, Andrew Hill, Umaporn Siangphoe, Kiat Ruxrungtham, Wisit Prasithsirikul, Ploenchan Chetchotisakd, Sasisopin Kiertiburanakul, Warangkana Munsakul, Phitsanu Raksakulkarn, Somboon Tansuphasawadikul, Reto Nuesch, David A. Cooper, Bernard Hirschel A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antiviral Therapy. Vol.10, No.6 (2005), 761-767. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/16783
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients
Other Contributor(s)
The HIV Netherlands Australia Thailand Research Collaboration
University of Liverpool
Chulalongkorn University
Bamrasnaradura Infectious Disease Institute
Khon Kaen University
Mahidol University
Vajira Hospital
San Pa Tong Hospital
Buddhachinnaraj Hospital
Universitatsspital Basel
Kirby Institute
Hopitaux universitaires de Geneve
University of Liverpool
Chulalongkorn University
Bamrasnaradura Infectious Disease Institute
Khon Kaen University
Mahidol University
Vajira Hospital
San Pa Tong Hospital
Buddhachinnaraj Hospital
Universitatsspital Basel
Kirby Institute
Hopitaux universitaires de Geneve
Abstract
Objective: To assess the efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir with two nucleoside reverse transcriptase inhibitors (NRTIs), as induction therapy before enrollment in a randomized trial of structured treatment interruption strategies. Design: Two-hundred antiretroviral-naive patients with CD4+ cell counts between 200-350 at screening were enrolled in this open-label 24week study. Methods: Patients were followed up every 8 weeks for CD4+ cells, HIV RNA, and clinical and laboratory toxicities. Results: Two-hundred patients were enrolled with median baseline CD4+ cell count of 267 cells/μl and HIV RNA 50 118 (4.7 log10) copies/ml. After 24 weeks of treatment, 191 of 200 (96%) patients had below 400 copies/ml HIV RNA, with 177/200 (89%) below 50 copies/ml (intent to treat, missing equals failure method), with a median rise in CD4+ cell count of 122 cells/μl. There was no significant correlation between the minimum concentration of saquinavir and HIV RNA reductions at week 8 (P=0.957) or absolute HIV RNA at week 24 (P=0.77). Conclusion: First-line highly active antiretroviral therapy (HAART) with once-daily saquinavir/ritonavir plus two NRTIs showed strong antiviral efficacy over 24 weeks, and should be evaluated in larger prospective randomized clinical trials. © 2005 International Medical Press.